These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 36231027)
1. CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis. Han S; Hao H; Han H; Xue D; Jiao Y; Xie Y; Xu Y; Huangfu L; Fu J; Wang S; Sun H; Li P; Zhou Q Cells; 2022 Sep; 11(19):. PubMed ID: 36231027 [TBL] [Abstract][Full Text] [Related]
2. Fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition. Xiao G; Lu W; Yuan J; Liu Z; Wang P; Fan H J Transl Med; 2024 Jan; 22(1):99. PubMed ID: 38268032 [TBL] [Abstract][Full Text] [Related]
3. Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway. Li Z; Yang HY; Zhang XL; Zhang X; Huang YZ; Dai XY; Shi L; Zhou GR; Wei JF; Ding Q J Exp Clin Cancer Res; 2022 May; 41(1):168. PubMed ID: 35524313 [TBL] [Abstract][Full Text] [Related]
4. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin. Shen H; Yan W; Yuan J; Wang Z; Wang C J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562 [TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250 [TBL] [Abstract][Full Text] [Related]
6. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway. Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of collagen type X alpha 1 promotes the progress of triple-negative breast cancer via Wnt/β-catenin signaling. Peng J; Liu X; Mao Y; Lv M; Ma T; Liu J; Zhou Q; Han Y; Li X; Wang H Mol Carcinog; 2024 Aug; 63(8):1588-1598. PubMed ID: 38780151 [TBL] [Abstract][Full Text] [Related]
8. SHC4 orchestrates β-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation. Zhong W; Jian Y; Zhang C; Li Y; Yuan Z; Xiong Z; Huang W; Ouyang Y; Chen X; Song L; Liu P; Wang X Cancer Lett; 2024 Feb; 582():216516. PubMed ID: 38052369 [TBL] [Abstract][Full Text] [Related]
9. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012 [TBL] [Abstract][Full Text] [Related]
10. A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway. Xie W; Zhang Y; He Y; Zhang K; Wan G; Huang Y; Zhou Z; Huang G; Wang J Int J Biochem Cell Biol; 2018 Oct; 103():45-55. PubMed ID: 30096373 [TBL] [Abstract][Full Text] [Related]
11. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression. Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268 [TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/β-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer. Shome R; Sen P; Sarkar S; Ghosh SS Exp Cell Res; 2024 May; 438(1):114032. PubMed ID: 38583856 [TBL] [Abstract][Full Text] [Related]
13. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609 [TBL] [Abstract][Full Text] [Related]
14. YAP1-induced RBM24 promotes the tumorigenesis of triple-negative breast cancer through the β-catenin pathway. Chen X; Lin X; Xia X; Xiang X J Investig Med; 2024 Jun; 72(5):403-413. PubMed ID: 38441112 [TBL] [Abstract][Full Text] [Related]
15. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/β-catenin pathway via regulation of heat shock protein A4. Nan J; Hu X; Guo B; Xu M; Yao Y Bioengineered; 2022 Apr; 13(4):10564-10577. PubMed ID: 35442158 [TBL] [Abstract][Full Text] [Related]
17. H3K27ac-induced RHOXF2 activates Wnt2/β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer. Guo M; Wang R; Nie M; Zhang H; Wang C; Song C; Niu S Cell Signal; 2024 Aug; 120():111196. PubMed ID: 38697448 [TBL] [Abstract][Full Text] [Related]
18. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling. Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274 [TBL] [Abstract][Full Text] [Related]
19. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway. Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039 [TBL] [Abstract][Full Text] [Related]